travoprost Side Effects
Also known as: Travatan Z
Analysis of 8,423 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
8,423
Death-Related
323
3.8% of reports
Hospitalizations
1,103
13.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 323 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 203 |
| ASTHENIA | 15 |
| FALL | 15 |
| OFF LABEL USE | 15 |
| DYSPNOEA | 14 |
| PNEUMONIA | 14 |
| FATIGUE | 13 |
| ANAEMIA | 12 |
| DIARRHOEA | 11 |
| MYOCARDIAL INFARCTION | 11 |
| CARDIAC FAILURE CONGESTIVE | 9 |
| DEHYDRATION | 9 |
| HYPOTENSION | 9 |
| URINARY TRACT INFECTION | 8 |
| CARDIAC FAILURE | 7 |
| CONFUSIONAL STATE | 7 |
| CONSTIPATION | 7 |
| DIZZINESS | 7 |
| RENAL FAILURE | 7 |
| BACK PAIN | 6 |
Reactions in Hospitalization Reports
Top reactions in 1,103 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 100 |
| FATIGUE | 76 |
| PNEUMONIA | 75 |
| DIARRHOEA | 65 |
| ACUTE KIDNEY INJURY | 63 |
| PYREXIA | 63 |
| DIZZINESS | 62 |
| DEHYDRATION | 61 |
| NAUSEA | 59 |
| DYSPNOEA | 58 |
| HEADACHE | 58 |
| ASTHENIA | 55 |
| URINARY TRACT INFECTION | 51 |
| MALAISE | 49 |
| VOMITING | 45 |
| ANAEMIA | 43 |
| CONSTIPATION | 42 |
| HAEMOGLOBIN DECREASED | 39 |
| CONFUSIONAL STATE | 38 |
| PAIN | 38 |
Nearby — Related Medications
What the FAERS Data Reveals About travoprost Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 8,423 voluntary reports linked to travoprost and its brand equivalents (Travatan Z), spanning 2004 through 2025. Of those, 323 (3.8%) listed death as an outcome and 1,103 (13.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 39% male; age distribution skews toward 75+, with 1,283 reports in that bracket. The single most reported reaction is treatment failure with 1,945 submissions, followed by drug ineffective and ocular hyperaemia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.